Antimicrobial Resistance and Therapy of Salmonella Infections | CMAC

Antimicrobial Resistance and Therapy of Salmonella Infections

Clinical Microbiology and Antimicrobial Chemotherapy. 2009; 11(4):305-326

​ Ivanov A.S.
Salmonella Salmonella enterica resistance typhoid fever antimicrobial therapy
Section
Diseases and Pathogens
Type
Journal article
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2009; 11(4):305-326

Abstract

This review contains brief information on the epidemiology of salmonellosis as well as the modern classification and nomenclature of Salmonella genus. The main mechanisms of antimicrobial resistance in Salmonella and their prevalence are summarized. Data on antimicrobial resistance for the most common S. enterica erotypes are described in detail. International recommendations on susceptibility testing in routine practice are presented. The indications for antibiotic therapy and the ways of optimizing a choice of antimicrobials for the treatment of infections caused by nontyphoid Salmonella serotypes and typhoid/paratyphoid fever are provided. A focus on current antimicrobial treatment regimens for patients with Salmonella infections based on experimental and clinical data is made in this paper.

  • 1. Pessoa-Silva C.L., Toscano C.M., Moreira B.M., et al. Infection due to extended-spectrum β-lactamase-producing Salmonella enterica subsp enterica serotype infantis in a neonatal unit. J Pediatr 2002; 141:381-7.
  • 2. Nataro J.P., et al. Escherichia, Shigella and Salmonella. In: Murray P.R., e.a., eds. Manual of Clinical Microbiology. 9-th ed. Washington DC: ASM Press. 2007. P. 670-87.
  • 3. Parry C.M. Management of multiple drug-resistant Salmonella infections. In: Gillespie SH., ed. Management of Multiple Drug-Resistance Infections. Humana Press Inc., Totowa. 2004.P.189-208.
  • 4. Threlfall E.J., Fisher I.S.T., Berghold C., Edwards G., et al. Antimicrobial drug resistance in isolates of Salmonella enterica from cases of salmonellosis in humans in Europe in 2000: results of international multi-centre surveillance. Euro Surveill. 2003;8(2):41-5.
  • 5. Pegues D.A., Ohl M.E., Miller S.I. Salmonella species, including Salmonella typhi. In: Mandell GL, Bennett JE, Dolin R: Mandell, Douglas, and Bennett’s Principles and practice of infectious diseases. Ed.
  • 6. Philadelphia: Elsevier Churchill Livingstone, 2005.P.2636-54. 6. Parry C.M., Hien T.T., Dougan G., White N.J., Farrar J.J. Typhoid fever. N Engi J Med 2002;347:1770-82.
  • 7. Hohmann EL. Nontyphoidal salmonellosis. Clin Infect Dis 2001; 32:263-9.
  • 8. Ramos J.M., Garcia-Corbeira P., Aguado J.M., et al. Clinical significance of primary versus secondary bacteraemia due to nontyphoid Salmonella in patients without AIDS. Clin Infect Dis 1994; 19:777-80.
  • 9. Shimoni Z., Pitlik S., Leibovici L., et al. Nontyphoid Salmonella bacteremia: age-related differences in clinical presentation, bacteriology, and outcome. Clin Infect Dis 1999; 28:822-7.
  • 10. Chiu C.-H., Su L.-H., Chu C. Salmonella enterica serotype Choleraesuis: epidemiology, pathogenesis, clinical disease and treatment. Clin Microb Rev. 2004;17(2):311-22.
  • 11. Sirinavin S., Jayanetra P., Layangkul T. Predictors for extraintestinal infection in Salmonella enteritis in Thailand. Pediatr. Infect. Dis. J. 1988;7:44-8.
  • 12. Cohen J.I., Barllett J.A., Curey R. Extra-intestinal manifestations of Salmonella infections. Medicine (Baltimore). 1987;66:349-88.
  • 13. Jacobson M.A., Hahan S.M., Gerberding J.L., et al. Ciprofloxacin for Salmonella bacteremia in the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1989;110:1027-9.
  • 14. Vugia, D.J., Samuel M., Farley M.M., et al. Invasive Salmonella infections in the United States, FoodNet, 1996-1999: incidence, serotype distribution, and outcome. Clin Infect Dis 2004; 38 (Suppl. 3):S149-S156.
  • 15. Chiu C.H., Su L.H., Chu C., et al. Isolation of Salmonella enterica serotype choleraesuis resistant to ceftriaxone and ciprofloxacin. The Lancet. 2004;363:1285-6.
  • 16. Threlfall E.J. Antimicrobial drug resistance in Salmonella: problems and perspectives in food- and water-borne infections. FEMS Microbiol Rev 2002; 26:141-8.
  • 17. Jean S.-S., Wang J.-Y., Hsueh P.-R. Bacteremia caused by Salmonella enterica serotype Choleraesuis in Taiwan. J Microbiol Immunol Infect 2006; 39:358-65.
  • 18. Soravia-Dunand V.A., Loo V.G., Salit I.E. Aortitis due to Salmonella: report of 10 cases and comprehensive review of the literature. Clin Infect Dis 1999; 29:862-8.
  • 19. Prager R., Rabsch W., Streckel W., et al. Molecular properties of Salmonella enterica serotype Paratyphi B distinguish between its systemic and its enteric pathovars. J Clin Microbiol 2003; 41:4270-8.
  • 20. Farmer III J.J., Boatwricht K.D., Janda M.J. Enterobacteriaceae. Introduction and identification. In: Murray P.R., e.a., eds. Manual of Clinical Microbiology. 9-th ed. Washington DC: ASM Press, 2007. P. 649-69.
  • 21. Parkhill J., Dougan G., James K.D., et al. Complete genome sequence of a multiple drug resistant Salmonella enterica serovar Typhi CT18. Nature 2001; 413:848- 52.
  • 22. Shanahan P.M.A., Karamat K.A., Thomson C.J., Amyes S.G.B. Characterization of multi-drug resistant Salmonella typhi isolated from Pakistan. Epidemiol Infect 2000; 124:9-16.
  • 23. Threlfall E.J. Multiresistant Salmonella typhimurium DT104: a truly international clone. J Antimicrob Chemother 2000; 46:7-10.
  • 24. Lindsay E.A., Lawson A.J., Walker R.A., et al. Molecular characterisation of a multiresistant strain of Salmonella enterica serotype typhimurium DT204b responsible for an international outbreak of salmonellosis: importance of electronic exchange of gel data for outbreak investigations. Emerg Infect Dis 2002; 8:732-4.
  • 25. Wall P.G., Morgan D., Lamden K., et al. A case control study of infection with an epidemic strain of multiresistant Salmonella typhimurium DT104 in England and Wales. Commun Dis Rep CDR Rev 1994;4:R130-R135.
  • 26. Glynn M.K., Bopp C., Dewitt W., et al. Emergence of multidrug-resistant Salmonella enterica serotype typhimurium DT104 infections in the United States. N. Engl. J. Med. 1998;338:1333-8.
  • 27. Verdet C., Arlet G., Barnaud G., Lagragnge P.H., Philippon A. A novel integron in Salmonella enterica serovar enteritidis, carrying the bla(DHA-1) gene and its regulator gene ampR, originated from Morganella morganii. Antimicrob Agent Chemother 2000; 44:222-5.
  • 28. Gaillot O., Clement C., Simonet M., Philippon A. Novel transferable β-lactam resistance with cephalosporinase characteristics in Salmonella enteritidis. J Antimicrob Chemother 1997; 39:85-7.
  • 29. Dunne E.E., Fey P.D., Kludt P., et al. Emergence of domestically-acquired ceftriaxone-resistant Salmonella infections associated with AmpC β-lactamase. JAMA 2000; 284:3151-6.
  • 30. Hanson N.D., Moland E.S., Hossain A., et al. Unusual Salmonella enterica serotype typhimurium isolate producing CMY-7, SHV-9 and OXA-30 β-lactamases. J Antimicrob Chemother 2002; 49:1011-4.
  • 31. Armand-Lefevre L., Leflon-Guibout V., Bredin J., et al. Imipenem resistance in Salmonella enterica serovar wein related to porin loss and CMY-4 β-lactamase production. Antimicrob Agents Chemother 2003; 47:1165-8.
  • 32. Gaillot O., Clement C., Simonet M., Philippon A. Novel transferable β-lactam resistance with cephalosporinase characteristics in Salmonella enteritidis. J Antimicrob Chemother 1997; 39:85-7.
  • 33. Su L.H., Wu T.L., Chia J.H., et al. Increasing ceftriaxone resistance in Salmonella isolates from university hospital in Taiwan. J Antimicrob Chemother 2005; 55:846-52.
  • 34. Threlfall E.J., Skinner J.A., Graham A., et al. Resistance to ceftriaxone and cefotaxime in non-typhoidal Salmonella enterica in England and Wales. J Antimicrob Chemother 2000; 46:860-2.
  • 35. Villa L., Mammina C., Miriagou V., et al. Multidrug and broad-spectrum cephalosporin resistance among Salmonella enterica serotype enteritidis clinical isolates in southern Italy. J Clin Microbiol 2002; 40:2662-5.
  • 36. Molbak K., Baggesen D.L., Aarestrup F.M., et al. An outbreak of multidrug-resistant, quinolone-resistant Salmonella enterica serotype typhimurium DT104. N Engl J Med 1999; 341:1420-5.
  • 37. Ridley A., Threlfall E.J. Molecular epidemiology of antibiotic resistance genes in multire-sistant Salmonella typhimurium DT104. Microb Drug Resist 1998; 2:113-8.
  • 38. Lawson A.J., Dassama M.U., Ward L.R., Threlfall E.J. Multiply resistant (MR) Salmonella enterica serotype typhimurium DT 12 and DT 120: a case of MR DT 104 in disguise? Emerg Infect Dis 2002; 8:434-6.
  • 39. Boyd D., Cloeckaert A., Chaslus-Danela E., Mulvey M.R. Characterization of variant Salmonella genomic island 1 multidrug resistance regions from serovars typhimurium DT104 and agona. Antimicrob Agents Chemother 2002; 46:1714-22.
  • 40. Meunier D., Boyd D., Mulvey M.R., et al. Salmonella enterica serotype typhimurium DT 104 antibiotic resistance genomic island 1 in serotype paratyphi B. Emerg Infect Dis 2002;8:430-3.
  • 41. Nikaido H., Basina M., Nguyen V., Rosenberg E.Y. Multydrug efflux pump AcrAB of Salmonella typhimurium excretes only those beta-lactam antibiotics containing lipophilic side chains. J Bacteriol 1998; 180:4686-92.
  • 42. Casin I., Breuil J., Darchis J.P., Guelpa C., Collatz E. Fluoroquinolone resistance linked to GyrA, GyrB, and ParC mutations in Salmonella enterica typhimurium isolates in humans. Emerg Infect Dis 2003; 9:1455-7.
  • 43. Archambaud M., Gerbaud G., Labau E., Marty N., Courvalin P. Possible in-vivo transfer of β-lactamase TEM-3 from Klebsiella pneumoniae to Salmonella kedougou. J Antimicrob Chemother 1991; 27:427-36.
  • 44. Tassios P.T., Gazouli M., Tzelepi E., et al. Spread of Salmonella typlnmurium clone resistant to expanded-spectrum cephalosporins in three European countries. J Clin Microbiol 1999; 37:3774-7.
  • 45. Datta N., Richards H., Datta C. Salmonella typhi in vivo acquires resistance to both chloramphenicol and cotrimoxazole. Lancet 1981; 1:1181-3.
  • 46. Schwalbe R., Hoge C.W., Morris J.G., O’Halon P.N. Craw­ford RA, Gilligan PH. In vivo selection for transmissible drug resistance in Salmonella typhi during antimicrobial therapy. Antimicrob Agents Chemother 1990; 34:161-3.
  • 47. Aarestrup F.M., Wiuff C., Molbak K., Threlfall E.J. Is it time to change fluoroquinolone breakpoints for Salmonella spp.? Antimicrob Agents Chemother 2003; 47:827-9.
  • 48. Davis M.A., Hancock D.D., Besser T.E. Multiresistant clones of Salmonella enterica: the importance of dissemination. J Lab Clin Med 2002; 140:135-41.
  • 49. Llanes C., Kirchgesner V., Plesiat P. Propagation of TEM- and PSE-type β-lactamases among amoxycillinresistant Salmonella spp. isolated in France. Antimicrob Agents Chemother 1999; 43:2430-36.
  • 50. Ling J.M., Zhou G-M, Woo T.H.S, French G.L. Antimicrobial susceptibilities and β-lactamase production of Hong Kong isolates of gastroenteric salmonellae and Salmonella typhi. J Antimicrob Chemother 1991; 28:877-85.
  • 51. Ribot E.M., Wierzba R.K., Angulo F.J., Barrett T.J. Salmonella enterica serotype typhimurium DT104 isolated from humans, United States, 1985,1990, and 1995. Emerg Infect Dis 2002;8:387-91.
  • 52. Piddock L.J.V. Fluoroquinolone resistance in Salmonella serovars isolated from humans and food animals. FEMS Microbiol Rev 2002; 26:3-16.
  • 53. Winokur P.L., Brueggemann A., DeSalvo D.L., et al. Animal and human multidrug-resistant cephalosporinresistant Salmonella isolates expressing a plasmid mediated CMY-2 AmpC β-lactamase. Antimicrob Agents Chemother 2000; 44:2777-83.
  • 54. Kadhiravan T., Wig N., Kapil A., et al. Clinical outcomes in typhoid fever: adver­se impact of infection with nalidixic acid-resistant Salmo­nella typhi. BMC Infectious Diseases. 2005;5:37.
  • 55. Nakaya H., Yasuhara A., Yoshimura K., et al. Life-threatening infantile diarrhoea from fluoroquinolone resistant Salmonella enterica typhimurium with mutations in both gyrA and parC. Emerg Infect Dis 2003; 9:255-7.
  • 56. Varma J.K., Molbak K., Barrett T.J., Angulo F.J., et al. Antimicrobial-resistant nontyphoidal Salmonella is assotiated with excess bloodstream infections and hospitalizations. J Infect Dis 2005;191:554-61.
  • 57. Egorova S., Kaftyreva L., Grimont P.A., Weill F.X. Prevalence and characterization of extended-spectrum cephalosporin-resistant nontyphoidal Salmonella isolates in adults in Saint Petersburg, Russia (2002-2005). Microb Drug Resist 2007;13(2):102-7.
  • 58. Ko W.C., Yan J.J., Yu W.L., et al. A new therapeutic challenge for old pathogens: community-acquired invasive infections caused by ceftriaxone- and ciprofloxacinresistant Salmonella enterica serotype Choleraesuis. Clin Infect Dis 2005; 40:315-8.
  • 59. Jean S.S., Lee Y.T., Guo S.M., Hsueh P.R. Recurrent infections caused by cefotaxime- and ciprofloxacin-resistant Salmonella enterica serotype Choleraesuis treated successfully with imipenem. J Infect 2005; 51:163-5.
  • 60. Yan J.J., Chiou C.S., Lauderdale T.L., et al. Cefalosporin and ciprofloxacin resistance in Salmonella, Taiwan. Emerg Infect Dis 2005; 11:947-50.
  • 61. Szych J., Cieslik A., Paciorek J., Kaluzewski S. Antibiotic resistance in Salmonella enterica subsp. enterica strains isolated in Poland from 1998 to 1999. Int J Antimicrob Agents 2001; 18:37-42.
  • 62. Yildirmak T., Yazgan A., Ozcengiz G. Multiple drug resistance patterns and plasmid profiles of non-typhi salmonellae in Turkey. Epidemiol Infect 1998; 121:303-7.
  • 63. Rastegar L.A., Validi N., Ghaffarzadeh K., Shamshiri A.R. In vitro activity of cefixime versus ceftizoxime against Salmonella typhi. Pathol Biol (Paris) 1997; 45:415-9.
  • 64. Yang Y.J., Liu C.C., Wang S.M., et al. High rates of antimicrobial resistance among clinical isolates of nontyphoidal Salmonella in Taiwan. Eur J Clin Microbiol Infect Dis 1998; 17:880-3.
  • 65. Griggs D.J., Gensberg K., .Piddock L.J. Mutations in gyrA gene of quinolone-resistant Salmonella serotypes isolated from human and animals. Antimicrob Agents Chemother 1996; 40:1009-13.
  • 66. Threlfall E.J., Skinner J.A., Ward L.R. Detection of decreased susceptibility to ciprofloxacin in Salmonella enterica serotypes typhi and paratyphi A. J Antimicrob Chemother 2001; 48:740-1.
  • 67. Chinh N.T., Parry C.M., Ly N.T., et al. A randomized controlled comparison of azithromycin and ofloxacin for treatment of multidrug-resistant or nalidixic acid-resistant enteric fever. Antimicrob Agents Chemother. 2000; 44:1855-9.
  • 68. Wain J., Hoa N.T.T., Chinh N.T., et al. Quinolone-resistant Salmonella typhi in Viet Nam: molecular basis of resistance and clinical response to treatment. Clin Infect Dis. 1997; 25:1404-10.
  • 69. Heurtin-Le Corre C., Donnio P-Y., Perrin M., et al. Increasing incidence and comparison of nalidixic acidresistant Salmonella enterica subsp. enterica serotype typhimurium isolates from human and animals. J Clin Microbiol. 1999; 37:266-9.
  • 70. Molbak K., Gerner-Smidt, Wegener H.C. Increasing quinolone resistance in Salmonella enterica serotype enteritidis. Emerg Infect Dis. 2002; 8:514-5.
  • 71. Chiu C.H., Wu T.L., Su L.H., et al. The emergence in Taiwan of fluoroquinolone resistance in Salmonella enterica serotype choleraesuis. N Engi J Med. 2002; 346:413-9.
  • 72. Heisig P. High-level fluoroquinolone resistance in a Salmonella typhimurium isolate due to alterations in both gyrA and gyrB genes. J Antimicrob Chemother 1993; 32:367-77.
  • 73. Baucheron S., Imberechts H., Cahslus-Danda E., Clockaert A. The AcrB multidrug transporter plays a major role in high-level fluoroquinolone resistance in Salmonella enterica serovar typhimurium phage type DT204. Microb Drug Resist 2002; 8:281-9.
  • 74. Mehta G., Randhawa V.S., Mohapatra N.P. Intermediate susceptibility to ciprofloxacin in Salmonella typhi strains in India. Eur J Clin Microbiol 2001; 20:760-1.
  • 75. Tran J.H., Jacoby G.A. Mechanism of plasmid-mediated quinolone resistance. Proc Natl Acad Sci USA 2002; 99(8):5638–42.
  • 76. Malorny B., Schroeter A., Helmuth R. Incidence of quinolone resistance over the period 1986 to 1998 in veterinary Salmonella isolates from Germany. Antimicrob Agents Chemother 1999; 43:2278-82.
  • 77. Hakanen A., Kotilainen P., Jalava J., et al Detection of decreased fluoroquinolone susceptibility in salmonellas and validation of nalidixic acid screening test. J Clin Microbiol 1999; 37:3572-7.
  • 78. Morisini MI, Blazquez J, Negri MC, et al. Characterisation of a nosocomial outbreak involving an epidemic plasmid encoding for TEM-27 in Salmonella enterica subspecies enterica serotype othmarschen. J Infect Dis 1996; 174:1015-20.
  • 79. Mathai D., Toleman M.A., Walsh T.R., Jones R.N. Molecular determination of β-lactamases (BL) types found in Salmonella spp. isolated in India: report for the MYSTIC programme (2001). In: Program and Abstracts of the 42nd Interscience Conference of Antimicrobial Agents and Chemotherapy. San Diego, CA: American Society of Microbiology, 2002; Abstract C2-1276:104.
  • 80. Otkun M., Erdem B., Akata F., et al. Antibiotic resistance patterns and plasmid profiles of Salmonella typhimurium isolates in Turkey. Eur J Clin Microbiol Infect Dis 2001; 20:206-9.
  • 81. Bhutta Z.A., Farooqui B.J., Sturm A.W. Eradication of a multiple drug resistant Salmonella paratyphi A causing meningitis with ciprofloxacin. J Infect 1992; 25:215-9.
  • 82. Saha S.K., Taukder S.Y., Islam M., Saha S. A highly ceftriaxone-resistant Salmonella typhi in Bangladesh. Pediatr Infect Dis J 1999;18:387.
  • 83. Clinical and Laboratory Standards Institute. Perfomance Standards for Antimicrobial Susceptibility Testing; 16- th Informational Supplement. CLSI document M100- S16. 2006.Vol. 26 №. 3.
  • 84. Neill M.A., Opal S.M., Heelan J., et al. Failure of ciprofloxacin to eradicate convalescent fecal excretion after acute salmonellosis: experience during and outbreak in health care workers. Ann Intern Med 1991; 114:195-9.
  • 85. Thielman N.M., Guerrant R.L. Clinical practice. Acute infectious diarrhea. N Engl J Med 2004; 350(1):38-47.
  • 86. Sirinavin S., Garner P. Antibiotics for treating Salmonella gut infections. Cochrane Database Syst Rev 2000; 2: CD001167.
  • 87. Voltersvik P., Halstensen A., Langeland N., Solberg C.O., et al. Eradication of non-typhoid salmonellae in acute enteritis after therapy with ofloxacin for 5 and 10 days. J Antimicrob Chemother 2000; 46:457-9.
  • 88. Hamer D.H. Bacterial and viral diarrhea. In: Baddour L.M., Gorbach S.L., eds. Therapy of infectious diseases. Philadelphia: W.B. Saunders Company, 2003. p. 399-414.
  • 89. Halstensen A., Voltersvik P., Gossius G., et al. Doubleblind comparison of ofloxacin for 3 days and placebo in acute bacterial enteritis. Drugs. 1995; 49(Suppl. 2):454-6.
  • 90. Akalin H.E. Role of quinolones in the treatment of diarrhoeal diseases. Drugs. 1995; 49(Suppl. 2):128-31.
  • 91. Sirinavin S., Pokawattana L., Bangtrakulnondh A. Duration of nontyphoidal Salmonella carriage in asymptoma­tic adults. Clin Infect Dis. 2004;38:1644-5.
  • 92. Ball P., Mandell L., Niki Y., Tillotson G. Comparative tolerability of the newer fluoroquinolone antibacterials. Drug Saf. 1999;21(5):407-21.
  • 93. Danisovicova A., Brezina M., Belan S., et al. Magnetic resonance imaging in children receiving quinolones: no evidence of quinolone-induced arthropathy. A multicenter survey. Chemotherapy. 1994;40(3):209-14.
  • 94. Chysky V., Kapila K., Hullmann R., et al. Safety of ciprofloxacin in children: worldwide clinical experience based on compassionate use. Emphasis on joint evaluation. Infection. 1991;19(4):289-96.
  • 95. Chiu C.H., Lin T.Y., Ou J.T. In vitro evaluation of intracellular activity of antibiotics against non-typhoid Salmonella. Int J Antimicrob Agents 1999; 12:47-52.
  • 96. Chiu C., Lin T.Y., Ou J.T. A clinical trial comparing oral azithromycin, cefixime and no antibiotics in the treatment of acute uncomplicated Salmonella enteritis in children. J Paediatr Child Health 1999; 35:372-4.
  • 97. Wang J-H., Liu Y-C., Yen M-Y., et al. Mycotic aneurysm due to non-typhi Salmonella: report of 16 cases. Clin Infect Dis 1996; 23:743-7.
  • 98. Thapar N., Sanderson I.R. Diarrhoea in children: an interface between developing and developed countries. Lancet 2004; 363:641-53.
  • 99. Glynn M.K., Reddy V., Hutwagner L., et al. Prior antimicrobial agent use increases the risk of sporadic infections with multidrug-resistant Salmonella enterica serotype Typhimurium: a FoodNet case-control study, 1996-1997. Clin Infect Dis 2004; 38:S227-36.
  • 100. Hung C.C., Hung M.N., Hsueh P.R., et al. Risk of recurrent nontyphoid Salmonella bacteremia in HIV-infected patients in the era of highly active antiretroviral therapy and an increasing trend of fluoroquinolone resistance. Clin Infect Dis 2007; 45(Suppl 2):e60-7.
  • 101. Hamer D.H., Gorbach S.L. Use of the quinolones for treatment and prophilaxis of bacterial gastrointestinal infections. In: Andriole VT, ed. The quinolones. 3rd ed. San Diego: Academic Press, 2000. P. 303-23.
  • 102. Moss P. Infections of the gastrointestinal tract. In: Finch R.G., Greenwood D., Norrby S.R., and Whitley R.J., eds. Antibiotics and Chemotherapy: anti-infective agents and their use in therapy. 8-th ed. London: Churchill Livingstone, 2003; p. 667-81.
  • 103. Soe G.B., Overturf G.D. Treatment of typhoid fever and other systemic salmonelloses with cefotaxime, ceftriaxone, cefoperazone, and other newer cephalosporins. Rev Infect Dis 1987; 9:719-36.
  • 104. Dutta P., Rasaily R., Saha M.R., et al. Ciprofloxacin for treatment of severe typhoid fever in children. Antimicrob Agents Chemother 1993; 37:1197-9.
  • 105. Punjabi N.H., Hoffman S.L., Edman D.C., et al. Treatment of severe typhoid fever in children with high dose dexamethasone. Pediatr Infect Dis J 1988; 7:598- 600.
  • 106. Seoud M., Saade G., Uwaydah M., Azoury R. Typhoid fever in pregnancy. Obstet Gynecol 1988;71:711-4.
  • 107. Islam A., Butler T., Kabir I., Alam N.H. Treatment of typhoid fever with ceftriaxone for 5 days or chloramphenicol for 14 days: a randomized clinical trial. Antimicrob Agents Chemother 1993; 37:1572-5.
  • 108. Phuong C.X.T., Kneen R., Nguyen T.A., et al. Dong Nai Typhoid Study Group. A comparative study of ofloxacin and cefixime for treatment of typhoid fever in children. Pediatr Infect Dis J 1999; 18:245-8.
  • 109. Bhutta Z.A., Khan I.A., Molla A.M. Therapy of multidrug-resistant typhoid fever with oral cefixime versus intravenous ceftriaxone. Pediatr Infect Dis J 1994; 13:990-4.
  • 110. Frenck R.W Jr., Nakhia I., Sultan Y. Azithromycin versus ceftriaxone for the treatment of uncomplicated typhoid fever in children. J Infect Dis 2000; 31:1134-8.
  • 111. Matsumoto Y., Ikemoto A., Wakai Y., et al. Mechanism of therapeutic effectiveness of cefixime against typhoid fever. Antimicrob. Agents Chemother 2001; 45:2450-4.
  • 112. Memon I.A., Billo A.G., Memon I.I.I. Cefixime: an oral option for the treatment of multidrug-resistant enteric fever in children. South. Med. J. 1997; 90:1204-7.
  • 113. Girgis N.I., Sultan Y., Hammad O., Farid Z. Comparison of the efficacy, safety and cost of cefixime, ceftriaxone and aztreonam in the treatment of multidrug-resistant Salmonella typhi septicemia in children. Pediatr Infect Dis J 1995; 14(7):603-5.
  • 114. Smith M.D., Duong N.M., Hoa N.T.T., et al. Comparison of ofloxacin and ceftriaxone for short-course treatment of enteric fever. Antimicrob. Agents Chemother. 1994; 38:1716-20.
  • 115. Bhutta Z.A., Khan I.A., Shadmani M. Failure of shortcourse ceftriaxone chemotherapy for multidrug-resistant typhoid fever in children: a randomized controlled trial in Pakistan. Antimicrob. Agent Chemother 2000; 44:450-2.
  • 116. Malkin D., Koren G., Saunders E.F. Drug-induced ap­lastic anemia: pathogenesis and clinical aspects. Am J Pediatr Hematol Oncol. 1990; 4:402-10.
  • 117. Hardman J.G., Limbird L.E., Gilman A.G. In: Gilman A.G., ed. Goodman and Gilman’s The Pharmacological Basis of Therapeutics. 10th ed. New York, NY: McGrawHill, 2001; p.1249.
  • 118. Acharya G.P., Davis T.M.E., Ho M., et al. Factors affecting the pharmacokinetics of parenteral chloramphenicol in enteric fiver. J Antimicrob Chemother 1997; 40:91-8.
  • 119. Parry C.M. The treatment of multidrug-resistant and nalidixic acid-resistant typhoid fever in Viet Nam. Trans R Soc Trop Med Hyg 2004; 98:413-22.
  • 120. Finkelstein R., Markel C., Putterman A., et al. Waterbone typhoid fever in Haifa, Israel: clinical, microbiologic and therapeutic aspects of a major outbreack. Am J Med Sci 1988; 296:27-32.
  • 121. Hien T.T., Bethell D.B., Hoa N.T.T., et al. Short course of ofloxacin for treatment of multidrug-resistant typhoid. Clin Infect Dis 1995; 20:917-23.
  • 122. Bethell D.B., Day N.P.J., Dung N.M., et al. Pharmacokinetics of oral and intravenous ofloxacin in children with multidrug-resistant typhoid fever. Antimicrob. Agent Chemother 1996; 40:2167-72.
  • 123. Gasem M.H., Keuter M., Dolmans W.M.V., et al. Persistence of Salmonellae in blood and bone marrow: randomized controlled trial comparing ciprofloxacin and chloramphenicol treatments against enteric fever. Antimicrob Agents Chemother. 2003; 47:1727-31.
  • 124. Yee C.L., Duffy C., Gerbino P.G., et al. Tendon or joint disorders in children after treatment with fluoroquinolones or azithromycin. Pediatr Infect Dis J 2002; 21:525- 9.
  • 125. Thaver D., Zaidi A.K., Critchley J., Madni S.A., Bhutta Z.A. Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever). Cochrane Database Syst. Rev. 2005. Apr 18; (2):CD004530.
  • 126. Girgis N.I., Butler T., Frenck R.W., et al. Azithromycin versus ciprofloxacin for treatment of uncomplicated typhoid fever in a randomized trial in Egypt that includes patients with multidrug resistance. Antimicrob Agents Chemother 1999; 43:1441-4.
  • 127. Butler T., Frenck R.W., Johnson R.B., Khakhria R. In vitro effects of azithromycin on Salmonella typhi: early inhibition by concentrations less than the MIC and reduction of MIC by alkaline pH and small inocula. J Antimicrob Chemother 2001; 47(4):455-8.
  • 128. Butler T., Sridhar C.B., Daga M.K., Johnson R.B., et al. Treatment of typhoid fever with azithromycin versus chloramphenicol in a randomized multicentre trial in India. J Antimicrob Chemother 1999; 44:243-50.
  • 129. Parry C.M., Ho V.A., Phuong L.T., et al. Randomized controlled comparison of ofloxacin, azithromycin and ofloxacin-azithromycin combination for treatment of multidrug-resistant and nalidixic acid-resistante typhoid fever. Antimicrob Agent Chemother 2007; 51:819-25.
  • 130. Koc E., Turkyilmaz C., Atalay Y., Sen E. Imipenem for treatment of relapsing Salmonella meningitis in a newborn infant. Acta Paediatr Jpn 1997; 39:624-5.
  • 131. Digranes A., Solberg C.O., Sjursen H., et al. Antibiotic susceptibility of blood culture isolates of Enterobacteriaceae from six Norwegian hospitals 1991-1992. APMIS 1997; 105:854-60.
Views
0 Abstract
0 PDF
0 Crossref citations
Shared